Navigation Links
TransMessenger Transfection Reagent

For transfection of cells with siRNA in RNAi procedures Features and benefits
  • Efficient transfection of siRNA for effective gene silencing
  • Quick and easy setup
  • Ready-to-use reagent
  • Tested for absence of RNase activity
Principle TransMessenger Transfection Reagent facilitates effective gene silencing in RNAi procedures by providing efficient transfection of siRNA into eukaryotic cells using a fast and easy procedure (see figure "Efficient Transfection of Primary Neuronal Cells Using QIAGEN siRNA and TransMessenger Reagent"). The reagent is a lipid-based formulation that is used in conjunction with a specific RNA-condensing enhancer and an optimized buffer to form siRNA-TransMessenger Reagent complexes that are efficiently transferred into eukaryotic cells. Strict quality control is performed to test for absence of RNase activity, lot-to-lot consistency, and low endotoxin levels (=10 EU/ml). Our rigorous standards eliminate reagent variables that can adversely affect the efficiency of siRNA transfection. Efficient Transfection of Primary Neuronal Cells Using QIAGEN siRNA and TransMessenger Reagent Primary neuronal cells from rats were transfected with a control nonspecific siRNA or an siRNA directed against microtubule-associated protein 2 (MAP2) using TransMessenger Transfection Reagent. Two days after transfection, cells were fixed, permeabilized, and stained using mouse monoclonal anti-MAP2 antibodies and Alexa Fluor 488-conjugated goa t anti-mouse secondary antibody (a-MAP2) and Alexa Fluor 594-conjugated phalloidin, which binds to f-actin and serves here as an expression control.

Data kindly provided by A.M. Krichevsky and K.S. Kosik, Brigham and Womens Hospital, Harvard Medical School, Boston, MA (from Krichevsky, A.M., and Kosik, K.S. (2002) RNAi functions in cultured mammalian neurons. Proc. Natl. Acad. Sci. USA 99, 11926. Copyright 2002 National Academy of Sciences, U.S.A.)

Procedure All TransMessenger Reagent components are provided as ready-to-use solutions. To generate TransMessenger-RNA transfection complexes, simply mix your siRNA with Enhancer R and Buffer EC-R and incubate for 5 minutes at room temperature, then add TransMessenger Reagent and incubate for a further 10 minutes. The complexes are mixed with medium and added directly to the cells. Following a 3 hour incubation, the medium is changed and the cells are incubated until they are ready for analysis.

Optimal transfection results are achieved using high-purity siRNA. The QIAGEN siRNA Oligo Synthesis Service offers custom siRNA oligos, a range of library siRNAs that target specific genes, non-silencing control siRNAs, and a set of siRNAs targeting genes linked with cancer; the Cancer siRNA Oligo Set Version 1.0.
Since the amount of siRNA used is a critical factor for successful transfection, we recommend optimizing the amounts of siRNA and TransMessenger Transfection Reagent for every cell type-siRNA combination. To facilitate this, the reagent is provided with guidelines and starting points for optimization of RNAi experiments.

App lications TransMessenger Reagent has been used to mediate successful RNAi in several studies using different cell types. For an up-to-date list of references and the latest developments in QIAGEN products for RNAi visit the Transfection Tools site at www.qiagen.com/transfectiontools.


'"/>

Source:


Page: All 1 2 3

Related biology technology :

1. TransMessenger Transfection Reagent
2. Efficient DNA transfection of primary CNS neurons using TransMessenger Transfection Reagent
3. TransMessenger Transfection Reagent Handbook
4. Efficient RNAi-mediated gene silencing in neuronal cells using QIAGEN siRNA and TransMessenger Transfection Reagent*
5. Highest Transfection Efficiency of an Endotoxin-Sensitive Mammalian Cell Line
6. Optimizing Transfection Conditions for Studying Signal Transduction Pathways
7. Transfection of Green Fluorescent Protein into Human Adrenalcarcinoma Cells
8. Improve Lipid- or Calcium Phosphate-Mediated Transfection of Human Dermal Fibroblasts
9. Versatile Transfection Reagent Offers Low Toxicity and Consistent Performance
10. Low-Toxicity, Lipid-Mediated Transfection of Mammalian Cells
11. Mycoplasma Contamination Reduces the Effect of Lipid-Mediated Transfection of Mammalian Cells
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/18/2017)... , ... May 18, 2017 , ... When James Sherley, was notified earlier this year ... Valuable Brands for the Year 2017 by The Silicon Review , he was not ... good progress increasing Asymmetrex’s value, but this recognition by Silicon Valley was particularly meaningful. ...
(Date:5/16/2017)... May 16, 2017 Telehealth has long ... and something that has been kept completely separate ... But according to   Logicalis Healthcare Solutions , ... IT solutions and managed services provider ( www.us.logicalis.com ... overlooked – interrelationship between telehealth, imaging, and EHR ...
(Date:5/15/2017)... ... 2017 , ... Algenist is continuing to disrupt the skincare ... with a patented formula, clinically proven to deliver visible firming results in 10 ... to our already innovative ELEVATE product line,” said vice president of product development ...
(Date:5/11/2017)... BOTHELL, Wash. , May 11, 2017   BioLife ... developer, manufacturer and marketer of proprietary clinical grade cell and ... media ("BioLife" or the "Company"), today reported operational highlights and ... Revenue from biopreservation media product sales reached a new high ... increase of 28% over the same period in 2016. Revenue ...
Breaking Biology Technology:
(Date:4/5/2017)... April 5, 2017  The Allen Institute for Cell ... Explorer: a one-of-a-kind portal and dynamic digital window into ... data, the first application of deep learning to create ... cell lines and a growing suite of powerful tools. ... these and future publicly available resources created and shared ...
(Date:4/5/2017)... KEY FINDINGS The global market for stem ... 25.76% during the forecast period of 2017-2025. The rise ... growth of the stem cell market. Download ... The global stem cell market is segmented on the ... cell market of the product is segmented into adult ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
Breaking Biology News(10 mins):